Navigation Links
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Date:1/24/2008

-- Recommendation based on study results demonstrating survival advantage

of 18.4 months when added to standard therapy -- First study to show survival advantage over European standard of care

BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced that the European Medicines Agency (EMEA) has issued a positive opinion to recommend approval of Thalidomide Pharmion(R) for use in combination with melphalan and prednisone as first line treatment for patients with untreated multiple myeloma (MM), aged 65 years or older or ineligible for high dose chemotherapy. The marketing authorization application (MAA) for Thalidomide Pharmion was submitted to the EMEA in January 2007.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) reviewed the application, and its positive opinion will be forwarded to the European Commission (EC), which generally follows, but is not obligated to follow, the recommendation of the CHMP, and issues final marketing approval within two to three months. Once ratified by the EC, a single marketing authorization would be granted to Pharmion to market Thalidomide Pharmion for first line multiple myeloma in the 27 member states of the European Union (EU) as well as Norway and Iceland.

"We are very pleased with this recommendation by the EMEA for the approval of Thalidomide in the treatment of first line multiple myeloma, and clearly appreciate that the return of Thalidomide to Europe as an approved therapy represents a significant step toward the safe distribution of this important and widely used drug for patients with multiple myeloma," said Patrick J. Mahaffy, Pharmion's president and chief executive officer. "This has been a lon
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
3. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
5. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
6. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
7. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
8. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
11. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... District of Saanich confirming the ... allows for commercial distribution of medical marijuana under the ...
(Date:3/31/2015)... AVIV, Israel, March 31, 2015  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, today announced ... 31, 2014. Fourth Quarter 2014 Highlights: ... featuring a keynote address by Professor Rohit Loomba, ...
(Date:3/31/2015)... March 31, 2015   Unique Pharmaceuticals , a ... complete and the company has initiated sterile compounding operations ... goal as a company is to meet and exceed ... . "Meeting the new regulations is validation of our ... the future of our industry, investing in its continued ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
... Pharmaceuticals announced today that it has been awarded ... (SBIR) grant by the National Cancer Institute (NCI). ... Multiforme" was awarded September 28, 2010 and covers ... follows their September 20, 2010 announcement selecting Bexion ...
... Inc. today announced the Company,s unique PERPOS® Percutaneous ... New Technology in Cervical Card Award at The ... in Orlando, FL, on October 4, 2010. ...   http://www.newscom.com/cgi-bin/prnh/20100419/LA88318LOGO ) The winners were ...
Cached Medicine Technology:Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI) 2Interventional Spine®, Inc. Awarded the 2010 Best New Technology in Cervical Care Award 2
(Date:3/31/2015)... 31, 2015 Horizon Blue Cross Blue ... its efforts to combat health insurance fraud resulted in ... of monies recovered and losses avoided -- in 2014. ... Horizon BCBSNJ created its fraud fighting, Special Investigations Unit ... efforts have saved members $261 million. , “Our ...
(Date:3/31/2015)... Altima Technologies, Inc., the maker ... documenting and diagramming data center assets and audio-video ... Manufacturer / Device Model, Dell N3000 Series, Dell ... Dell PowerEdge r630, Cisco Catalyst 3850 Series, HP ... 100K, VMAX 200K, VMAX 400K , “With NetZoom ...
(Date:3/31/2015)... The Oliver Law Group, who ... notes that filings for testosterone lawsuits that allege ... complications associated with testosterone therapy products such as ... steady pace. The website for the U.S. District ... lawsuits have been centralized, shows 1,291 testosterone lawsuits ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 When SIGVARIS launched ... company’s most successful product launch to date. Women immediately fell ... is giving women another reason to love EVERSHEER with the ... for spring. , Lavender mist pairs perfectly with a ... neutral outfits. For women looking to add a hint of ...
(Date:3/31/2015)... 2015 India Network Foundation , ... a travel advisory to all USA bound international travelers ... United States are higher than many other countries and ... For example, a coronary artery bypass graft costs ... about $34,358 . Visitors are advised to get ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:Altima Adds More Hardware Devices to its NetZoom™ Visio® Stencils Device Library 2Health News:Testosterone Lawsuit Filings Rise To Over 1,200 In Multidistrict Litigation Pending In Northern Illinois Federal Court Reports The Oliver Law Group 2Health News:Testosterone Lawsuit Filings Rise To Over 1,200 In Multidistrict Litigation Pending In Northern Illinois Federal Court Reports The Oliver Law Group 3Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3
... February 16, 2011 An article published in a forthcoming ... of the first to provide evidence of the effectiveness ... suffering from posttraumatic stress disorder (PTSD). The study shows ... in PTSD symptoms after an average of seven treatment ...
... Sciences, National Academy of Engineering, Institute of Medicine, and National ... annual meeting of the American Association for the Advancement of ... Washington, D.C. Tribute to Stephen H. ... East (Renaissance Downtown), Stephen Schneider, a renowned climate scientist at ...
... 16, 2011 − One of the tough challenges a parent ... parent the surviving children, and the task begins immediately, according ... moment their child dies, parents are faced with the two ... a child and the ongoing, daily demands from their surviving ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) ... when they,re first tested may not need to be screened ... new study suggests. Dutch researchers presenting the findings ... few men with a PSA below 3.0 ng/ml were likely ...
... newly diagnosed with Alzheimer,s disease or other dementias, and ... how to plan for the patient,s progressive loss of ... by a physician at the San Francisco VA Medical ... "When a patient is diagnosed with Alzheimer,s disease or ...
... -- Psychotherapy triggers changes in the brains of people ... Medication and psychotherapy are used to treat people with ... overwhelming fear of interacting with others and of being ... the neurological effects of psychotherapy (talk therapy) than on ...
Cached Medicine News:Health News:Innovative virtual reality exposure therapy shows promise for returning troops 2Health News:Media advisory -- events at AAAS 2Health News:Media advisory -- events at AAAS 3Health News:Media advisory -- events at AAAS 4Health News:Parenting after the death of a child a difficult balancing act: York U study 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 3Health News:Financial planning a key but neglected component of Alzheimer's care, say researchers 2Health News:'Talk Therapy' Can Alter Brain Activity, Research Shows 2
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... , Standby: All toggle switches at off (center ... 10 s (1 pulses/10 s) , Tetanus: 50 ... , Train-Of-Four: Single (4 pulses/2 s); repeat (4 ... Current: Adjustable from 0-70 mA(HI range) 0-6.0mA (LO ...
... of Operation: , Standby: A standby switch maintains ... , Twitch: 1 s (1 pulse/s); 2 Hz ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz ... repeats every 10 s , Output Current: Adjustable ...
Medicine Products: